STOCK TITAN
  1. Home
  2. Sec-filings
  3. CPRX
  4. [Form 4] CATALYST PHARMACEUTICALS, INC. Insider Trading Activity

Catalyst Pharma insider reports new options and RSUs on Form 4

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Catalyst Pharmaceuticals (CPRX) reported insider equity activity by its Chief Operating and Scientific Officer on a Form 4. On November 20, 2025, the officer received options to purchase 158,454 shares of common stock at an exercise price of $22.77 per share. These options vest in three equal installments on November 20, 2026, November 20, 2027, and November 20, 2028.

Also on November 20, 2025, the officer was granted 47,826 restricted stock units (RSUs), with shares delivered upon vesting. A separate RSU award vests in three equal tranches on November 21, 2025, November 21, 2026, and November 21, 2027, and shares must be delivered within sixty days of each vesting date; the first tranche of 8,267 shares was delivered on November 21, 2025. Following these transactions, the officer directly owned 1,067,930 shares of common stock.

Positive

  • None.

Negative

  • None.
Insider Miller Steve
Role Chief Op. & Scientific Officer
Type Security Shares Price Value
Exercise Restricted Stock Units 8,267 $0.00 --
Exercise Common stock, par value $0.001 per share 8,267 $0.00 --
Grant/Award Options to purchase common stock 158,454 $0.00 --
Grant/Award Restricted Stock Units 47,826 $0.00 --
Holdings After Transaction: Restricted Stock Units — 1,497,522 shares (Direct); Common stock, par value $0.001 per share — 1,067,930 shares (Direct); Options to purchase common stock — 1,457,963 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027, and 1/3rd on November 20, 2028. Shares of common stock will be delivered to the Reporting Person upon vesting. Derivative securities vest in three equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Miller Steve
(Last) (First) (Middle)
355 ALHAMBRA CIRCLE, SUITE 801
(Street)
CORAL GABLES FL 33134
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CATALYST PHARMACEUTICALS, INC. [ CPRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Op. & Scientific Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock, par value $0.001 per share 11/21/2025 M 8,267 A (1) 1,067,930 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options to purchase common stock $22.77 11/20/2025 A 158,454 (2) 11/20/2032 Common Stock 158,454 $0 1,457,963 D
Restricted Stock Units (3) 11/20/2025 A 47,826 (2) (3) Common Stock 47,826 $0 1,489,255 D
Restricted Stock Units (3) 11/21/2025 M 8,267 (4) (5) Common Stock 8,267 $0 1,497,522 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
2. Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027, and 1/3rd on November 20, 2028.
3. Shares of common stock will be delivered to the Reporting Person upon vesting.
4. Derivative securities vest in three equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027.
5. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.
/s/ Steve Miller 11/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did CPRX report in this Form 4?

The Chief Operating and Scientific Officer of Catalyst Pharmaceuticals (CPRX) reported new grants of stock options and restricted stock units (RSUs), along with the delivery of shares from a vesting RSU tranche.

How many stock options were granted to the CPRX officer and at what price?

The officer received options to purchase 158,454 shares of CPRX common stock at an exercise price of $22.77 per share.

What is the vesting schedule for the newly granted CPRX stock options?

The options vest in three equal tranches: November 20, 2026, November 20, 2027, and November 20, 2028.

How many restricted stock units were granted to the CPRX executive?

The executive was granted 47,826 restricted stock units, with each RSU representing a contingent right to receive one share of CPRX common stock upon vesting.

What RSU vesting and share delivery occurred on November 21, 2025 for CPRX?

An RSU award that vests in three equal tranches delivered the first tranche of 8,267 CPRX shares on November 21, 2025, with future tranches scheduled for November 21, 2026 and November 21, 2027.

How many CPRX common shares does the officer own after these transactions?

After the reported transactions, the officer directly owned 1,067,930 shares of Catalyst Pharmaceuticals common stock.